Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced the publication of Phase 3 RELIEF trial results for TNX-102 SL, a non-opioid treatment for fibromyalgia management. The study showed significant reductions in daily pain, improved sleep, and reduced fatigue, with the treatment being safe and well-tolerated.
June 15, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' Phase 3 RELIEF trial results for TNX-102 SL show significant pain reduction and improved sleep for fibromyalgia patients, potentially boosting the company's stock.
The positive results from the Phase 3 RELIEF trial of TNX-102 SL indicate that the treatment is effective and safe for fibromyalgia patients. This could lead to increased interest in the company's stock as investors anticipate potential FDA approval and commercialization of the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100